Anaplastic oligodendroglioma: a new treatment paradigm and current controversies (Q39373950)

11 September 2017

title

Anaplastic oligodendroglioma: a new treatment paradigm and current controversies (English)

1 reference

anaplastic oligodendroglioma

11 September 2017

1 reference

1 reference

inferred from title

adult oligodendroglioma

1 reference

3

Michael Weller

1 reference

11 September 2017

2

Wolfgang Wick

1 reference

11 September 2017

1

Patrick Roth

1 reference

11 September 2017

publication date

1 December 2013

1 reference

Current Treatment Options in Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

14

1 reference

11 September 2017

issue

4

1 reference

11 September 2017

page(s)

505-513

1 reference

The 2007 WHO classification of tumours of the central nervous system

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Molecular neuro-oncology in clinical practice: a new horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Successful chemotherapy for recurrent malignant oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Aggressive oligodendroglioma: a chemosensitive tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Survey of treatment recommendations for anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Initial treatment patterns over time for anaplastic oligodendroglial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Penetration of intra-arterially administered vincristine in experimental brain tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0251-7

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p

21 January 2018

1 reference

12 December 2020

The role of postoperative irradiation in the treatment of oligodendroglioma.

1 reference

12 December 2020

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management

1 reference

12 December 2020

10.1007/S11864-013-0251-7

Identifiers

DOI

1 reference

11 September 2017

1 reference